Company intelligence / Profile preview

Fraserwoods

South Korea

Ownership: Private
Development stage: Other

Overview

Fraser Therapeutics has demonstrated technical leadership in targeted protein degradation through awards (BMS Innovation Challenge 2022, Boehringer Ingelheim Innovation Prize Japan 2023), with a pipeline targeting neurodegeneration and cancer; no disclosed clinical results yet

Therapeutic areas: OncologyNeurology
Modalities: Small moleculeProteolysis-targeting chimera
Industry: Biotech

Partnerships

Johnson & Johnson Innovation – JJDC, Inc. (lead investor, JLABS member)Premier PartnersK2 InvestmentsMirae Asset CapitalQuad Asset ManagementSTIC VenturesCompany K PartnersKiwoom InvestmentsSmilegate Investments

Beyond the preview

Go deeper on Fraserwoods.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Fraserwoods.

Explore the full profile